OKYO
OKYO Pharma Ltd - New (OKYO)
Healthcare • NASDAQ • $1.39-1.19%
- Symbol
- OKYO
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.39
- Daily Change
- -1.19%
- Market Cap
- $74.00M
- Trailing P/E
- N/A
- Forward P/E
- -2.14
- 52W High
- $3.20
- 52W Low
- $1.27
- Analyst Target
- $8.33
- Dividend Yield
- 0.00%
- Beta
- -0.06
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Company websiteResearch OKYO on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.